Literature DB >> 35361742

Fate of Asymptomatic Limb after Kissing Stents in Aortoiliac Occlusive Disease.

Faheem Asem Ahmad1, Martin Michael Hennessy1, Alexander Fredrik Nath1.   

Abstract

Purpose: Kissing stent angioplasty is an established endovascular treatment strategy for stenosis at the aortic bifurcation but not without its detractors. This study aimed to analyze the outcomes of kissing stents with regard to stent occlusion and complications in which an asymptomatic limb was treated. Materials and
Methods: A total of 106 patients undergoing aortic bifurcation intervention from January 2015 to November 2020 were retrospectively reviewed. Only patients with at least one common iliac artery (CIA) ostium and undergoing bilateral CIA intervention were included in the study.
Results: Patients were followed up for a median period of 26 months (interquartile range, 21-51 months). The TransAtlantic InterSociety Consensus (TASC)-II classification of lesions was as follows: A, 49%; B, 41%; C, 6%; and D, 5%. The treatment indication was limited to one side in 53% of patients. Technical and procedural success rates were 99% and 90%, respectively. Ischemic events in an asymptomatic limb occurred in 6% of cases, 3% due to late stent thrombosis >30 days, and 3% due to progression of downstream infrainguinal disease. Primary and secondary patency rates at 1, 3, and 5 years were 98%, 87%, and 85%, and 99%, 94%, and 94%, respectively. Periprocedural mortality developed in two patients with no amputation.
Conclusion: Kissing stent deployment is a safe and effective strategy for the treatment of aortoiliac bifurcation disease. Unfavorable outcomes due to stenting in the asymptomatic iliac artery are very rare. Long-term surveillance is necessary due to the risk of late thrombosis or downstream disease progression.

Entities:  

Keywords:  Atherosclerosis; Iliac artery; Interventional radiology; Peripheral arterial disease; Stent

Year:  2022        PMID: 35361742      PMCID: PMC8971782          DOI: 10.5758/vsi.210074

Source DB:  PubMed          Journal:  Vasc Specialist Int        ISSN: 2288-7970


INTRODUCTION

Endovascular treatment has gained an increasing preference for the treatment of complex aortoiliac vascular diseases [1]. Aortobifemoral (ABF) bypass may yield better long-term patency rates but is associated with significant postoperative morbidity (8%-13%; including hemorrhage, sepsis, and heart failure) and mortality (up to 5%) [2-5]. Percutaneous approaches allow for faster patient recovery and shorter inpatient stay. Endovascular intervention is recommended for less complex lesions graded TASC-II class A and B, with comparable short- and medium-term outcomes now being shown for classes C and D [1,6]. Küffer et al. [7] pioneered the kissing stent technique for reconstruction of the aortic bifurcation. During this procedure, stents are placed across both limbs of the common iliac artery (CIA) and inflated simultaneously. This approach minimizes plaque shift, preserves the native ostia, and reduces distal embolization down the contralateral unaffected limb [8,9]. Concerns remain regarding vessel dissection and thrombosis, particularly in asymptomatic or undiseased limbs [9-12]. The data remains sparse, with many studies hampered by small patient numbers and limited follow up periods [13]. Dated studies have also failed to reflect improvements in outcomes using contemporary stent technology and procedural techniques. Substantive demand has arisen for viable endovascular alternatives, where surgery is no longer a viable option, such as advanced age and comorbidities. We aimed to review our practice of kissing stents in a tertiary vascular referral center and analyze the outcomes of kissing stents focusing on stent occlusion and complications in which an asymptomatic limb was treated. This study was reviewed by the West of Scotland NHS Research Ethics Service and a formal ethical review was waived (West of Scotland REC 1 IRB 00002179). The written informed consent was waived by the ethics committee.

MATERIALS AND METHODS

The local radiology information system was manually reviewed to identify all aortoiliac intervention cases from January 2015 to November 2020 at our tertiary center. Case records were analyzed to determine whether patients met the inclusion criteria. Patient inclusion was limited to true aortoiliac disease at the bifurcation with involvement of at least one CIA ostium up to 1 cm from the bifurcation, and bilateral kissing intervention (either balloon angioplasty or stent) was performed. All patients underwent endovascular intervention through a multidisciplinary team (MDT) review comprising vascular surgeons and interventional radiologists. The practical criteria for choosing a kissing versus single-stent approach were left to the discretion of the individual teams. In general, a kissing stent approach was selected for complex aortoiliac bifurcation lesions involving the distal aorta and bilateral ostia of CIAs, and asymmetric aortoiliac lesions involving the unilateral CIA ostium, as per the currently accepted best practice. Fluoroscopic angiographic images were examined by an interventional radiologist to determine the TransAtlantic InterSociety Consensus (TASC) classification. Operative records were reviewed to acquire baseline demographic variables, categorize pre-interventional symptoms according to the Fontaine classification system, and determine if symptoms were unilaterally distributed [14]. Each case record was reviewed longitudinally to determine procedural success, in-hospital complications, and the incidence of late ischemic vascular events defined as recurrent intermittent claudication, stent occlusion, unplanned major amputation, and vascular re-intervention either at the CIA level or more distally. For cases in which intervention was performed on an asymptomatic leg, any subsequent complications to that leg were explored in more qualitative detail. Vascular access was achieved through bilateral femoral artery punctures, either percutaneously or directly, if the patient underwent concurrent endarterectomy. Lesions were crossed using various methods, either luminal or subintimal, but in all cases, luminal re-entry was confirmed prior to treatment, and the lesion was treated from lumen to lumen. The selection of stent type and size was left to the discretion of the interventionalist. Stents were deployed simultaneously to ensure that the vessel flow and ostial integrity were not compromised during contralateral vessel treatment. All patients received maintenance antiplatelet therapy (aspirin 75 mg once daily) for at least one week before the intervention and intra-arterial heparin (50-100 IU/kg) during the procedure. Patients who were already taking clopidogrel before the intervention continued this afterward. All procedures were performed under local anesthesia using vascular closure devices at the end of the procedure. Completion angiography was performed in all cases. Technical success was defined as residual stenosis of ≤30%. The patients underwent standard clinical follow-up at 3 to 6 months with ankle-brachial pressure index and duplex scan assessments. Further imaging, such as computed tomography angiography, magnetic resonance angiography, or invasive angiography, was performed only if clinical assessment raised suspicion of vessel restenosis or re-occlusion. Patency was classified as per Society of Vascular Surgery - International Society for Cardiovascular Surgery (SVS-ISCS) Guidelines [15].

RESULTS

1) Patient demographics

A total of 106 patients were followed for a median period of 26 months (interquartile range [IQR], 21-51 months). None of the patients was lost to follow-up. The mean age was 66±10 years, with a balanced sex distribution (51% male, 49% female). Cardiovascular comorbidities and risk factors are described in Table 1. Unilateral symptoms were observed in 56 patients (53%). The chief complaints were claudication (60%) and chronic limb-threatening ischemia (CLTI, 40%). Most lesions were classified as either TASC A (49%) or TASC B (41%). In 34 cases (32%), at least one CIA was occluded.
Table 1

Clinical characteristics of kissing stent angioplasty (n=106)

Clinical characteristicNumberRatio (%)
Sex, male5451
Risk factors
Hypertension5451
Diabetes mellitus3432
Chronic kidney disease1211
Smoker/ex-smoker10094
Pre-interventional Fontaine classification
II6460
III1918
IV2322
Symptom distribution
Unilateral5653
Bilateral5047
Occlusion
Complete occlusion3432
Stenosis7268
TASC-II classification
A5249
B4341
C66
D55

TASC, Trans Atlantic Inter-Society Consensus.

2) Procedural outcomes

Technical success was achieved in 99% of the cases, except in one where a heavily calcified occlusion could not be safely crossed. The procedural mortality rate was 2% due to thoracic aortic dissection and abdominal aortic rupture, and the periprocedural in-hospital complication rate was 9% (Table 2). The 30-day all-cause mortality rate was 3%. Major complications included aortic rupture (two cases) and groin pseudoaneurysm (two cases managed with thrombin injection). A kissing stent strategy was employed in 89 patients (84%), with the remainder being treated with simultaneous balloon angioplasty. The stent diameter ranged from 6 to 10 mm. Balloon-expandable stents were most commonly used in 61 patients (58%), followed by self-expanding stents in 11 patients (10%) for tortuous vessels and covered stents in 17 patients (16%) for more calcified arteries (Table 3). Most patients (73%) were treated with stainless steel stents, and 33 patients (31%) were discharged on the same day of the procedure. None of the patients required conversion to an open surgery.
Table 2

In-hospital outcomes

Variablen (%)Description
Technical success105 (99)-
Cumulative complications9 (9)-
Intra-procedural complication5 (5)-
Death2Thoracic aortic dissection, abdominal aortic rupture
Vessel dissection2Occlusion of external iliac artery requiring additional stenting
Distal embolization1Thrombus in tibioperoneal trunk
Post-procedural complication4 (4)-
Femoral pseudo-aneurysm2Requiring thrombin injection
Hematoma1Delayed discharge
Groin infection1Prolonged in-patient stay and antibiotics
Table 3

Devices utilized

DeviceNumber
Balloon expandable stent
Visipro (Medtronic, Minneapolis, MN, USA)61
Self expandable stent
Smart (Cordis, Miami Lakes, FL, USA)9
Zilver (Cook Medical, Bloomington, IN, USA)2
Covered stent
Advanta (Atrium Medical, Charlotte, NC, USA)15
Viabahn (Gore Medical, Flagstaff, AZ, USA)1
VBX (Gore Medical)1
Balloon only17

3) Follow-up outcomes

During the study period, 21 patients (20%) died of cardiovascular and non-cardiovascular causes, with a median period free from recurrent events of 22 months (IQR, 9.6-38). The number of patients free of recurrence-defined peripheral vascular events at 1, 3, and 5 years was 88%, 70%, and 59%, respectively (Fig. 1). Kaplan–Meier analyses of primary and secondary patency rates were 98% and 99% at 1 year, 87% and 94% at 3 years, and 85% and 94% at 5 years, respectively (Fig. 1, 2). Six ischemic events occurred in patients with an asymptomatic limb. Review of primary care notes and prescription data did not reveal any lack of compliance with secondary-prevention pharmacotherapy. Three cases were due to late (>30 days) stent thrombosis resulting from aortoiliac intervention (Table 4). One patient presented with unilateral occlusion and underwent ABF grafting at 6 weeks. Two patients presented with bilateral stent occlusion at 4 and 10 months. The former underwent surgical bypass, while the latter was managed conservatively due to comorbidities. The other three ischemic events in the asymptomatic limb were not related to aortoiliac intervention. All patients presented with worsening recurrent claudication due to downstream disease progression in the infrainguinal arteries, requiring surgical or endovascular intervention. Two patients underwent femoropopliteal bypass grafting at 12 and 24 months, and one patient underwent tibial angioplasty. Only one major amputation developed because of the progression of distal infrainguinal disease (Table 5).
Fig. 1

Kaplan–Meier survival curves showed freedom from recurrent events (recurrent intermittent claudication, stent occlusion, vascular re-intervention to either common iliac artery or leg, and major amputation).

Fig. 2

Kaplan–Meier survival curves showed primary and secondary patency rates.

Table 4

Recurrent events in asymptomatic leg

Complicationn (%)TASC classificationStent typeDiameter (mm)Outcome
Related to CIA intervention3 (3)
Unilateral stent occlusion1BVisipro8Surgical ABG
Bilateral stent occlusion2AVisipro8Surgical ABG
BAdvanta7Conservative management
Unrelated to CIA intervention3 (3)
Femoral artery disease2ABalloon8Femoral-popliteal bypass
Tibial artery disease1AVisipro9Femoral-popliteal bypass
AVisipro10Tibial artery angioplasty

CIA, common iliac artery; ABG, aortic-bypass graft.

Table 5

Long term recurrent events

Complicationn (%)
Recurrent intermittent claudication28 (26)
Stent occlusion8 (8)
Re-intervention (common iliac artery)7 (7)
Re-intervention (leg)11 (10)
Amputation1 (1)

DISCUSSION

Endovascular therapy is a viable alternative to open surgery for the treatment of aortic bifurcation atherosclerosis. Surgical approaches with ABF grafts continue to carry burdensome in-hospital mortality and morbidity (3%-5% and 8%-13%, respectively) [2,3]. Published longer-term patency rates of ABF were better than those of endovascular therapy (87%-91% at 5 years), but this remains a challenge. To the best of our knowledge, this is the first study to specifically address concerns regarding the durability of this procedure in the unaffected contralateral leg in a substantive patient cohort. This study demonstrated a low frequency of adverse events in the asymptomatic limbs. No complications occurred in 97% of the patients and in three cases (3%), stent occlusion occurred but did not result in major amputation. When comparing these outcomes with other single-stent intervention studies, Suh et al. [16] reported that non-kissing stent strategies resulted in plaque shift to the undiseased limb, with a similar rate of urgent re-intervention required (3%). To date, only Mohamed et al. [13] provided specific data on asymptomatic contralateral limb complications. They recorded an event rate of 13%, with in-stent restenosis rather than occlusion being predominant. These data remain significantly limited by the small numbers (only 24 patients) and truncated follow-up periods (average of 2 years). While our larger study provides a degree of reassurance with a relatively low recorded number of adverse events, the incidence of stent occlusion emphasizes the ongoing importance of meticulous stent placement, appropriate stent sizing, and use of adjunctive antiplatelet therapy. Other factors, such as poor distal run-off and excessive stent protrusion (>20 mm) into the aorta, are postulated as negative influencers of outcome but remain speculative [17]. Our recorded procedural mortality rate of 2% and early 30 day mortality of 3% were within the range of previous reports (0%-2.3%) [13,18-20]. In our series, post-mortem analysis revealed that one patient died of thoracic dissection consequent to adrenergic stress rather than wire intervention (the guidewire also did not pass through the affected region of the thoracic aorta during fluoroscopic screening). Another cause of death was due to unrelated sepsis. Complications occurred in 9% of the patients, which is consistent with the literature (0%-12%). In addition, none of the patients required conversion to open surgery. Incidences of procedural complications and occlusion were also similar to those demonstrated for single-vessel iliac intervention, suggesting that the additive risk of placing an additional stent is marginal [21]. Primary patency rates in this study of 98%, 87%, and 85% (at 1, 3, and 5 years, respectively) compare favorably to larger substantive series enrolling >50 patients, such as by Yilmaz et al. (63% at 3 years) [22], Haulon et al. (79% at 3 years) [23], Björses et al. (65% at 5 years) [18], and Vértes et al. (77% at 5 years) [17] and begin to approach those of ABF grafts. These series reported higher reintervention rates of up to 30% compared to our observed 7%. The TASC lesion distribution was reflective of the current recommended practice; 90% of cases were classified as TASC-II A and B [1]. While this composition may suggest a favorable risk profile, other characteristics in this study group were associated with lesion complexity and poorer primary patency, including 60% CLTI, and 32% had at least one occluded CIA [18]. Although prospective randomized controlled trials comparing endovascular therapy against open surgery are lacking, small retrospective series studies suggest that comparable outcomes can be achieved with stent therapy even for more complex TASC C and D lesions [18,20,24]. Various factors may explain the improvement in procedural and patency outcomes. The routine use of vascular closure devices can reduce the risk of bilateral femoral punctures necessitated by the kissing-stent approach [25]. Newer drug eluting stents theoretically deliver more effective endothelial chemotherapy to dampen neointimal hyperplasia and restenosis, although a consensus on their safety remains pending [26]. Bioabsorbable polymers may further obviate concerns regarding the deployment of a foreign body in asymptomatic vessels [26]. The risk of vessel rupture from intervention in more complex calcified lesions can now be managed through the use of covered stents [27]. As individual and institutional experiences increase, overall proficiency correspondingly develops [28]. This dynamic is optimized by concentrating procedures into high-volume tertiary referral vascular centers. The strengths of this current study are its large number of patients and long follow-up period. All patients selected for endovascular intervention underwent an MDT review process to reduce selection bias and enhance the applicability to real-world practice. However, while retrospective studies have limitations, our study aimed to provide safety outcome data rather than overturn the existing evidence. There remains a need for high-quality multicenter randomized studies that compare endovascular and surgical techniques across more severe TASC lesion categories.

CONCLUSION

Kissing stent deployment is a safe and effective strategy for treating aortoiliac bifurcation diseases. Unfavorable outcomes due to stenting in the asymptomatic iliac artery are very rare. However, long-term surveillance is necessary due to the risk of late thrombosis or downstream disease progression.
  28 in total

1.  Kissing stents in the aortic bifurcation.

Authors:  F O Mendelsohn; R M Santos; J J Crowley; R J Lederman; F R Cobb; H R Phillips; N J Weissman; R S Stack
Journal:  Am Heart J       Date:  1998-10       Impact factor: 4.749

2.  Recommended standards for reports dealing with lower extremity ischemia: revised version.

Authors:  R B Rutherford; J D Baker; C Ernst; K W Johnston; J M Porter; S Ahn; D N Jones
Journal:  J Vasc Surg       Date:  1997-09       Impact factor: 4.268

3.  Stent Protrusion >20 mm Into the Aorta: A New Predictor for Restenosis After Kissing Stent Reconstruction of the Aortoiliac Bifurcation.

Authors:  Miklós Vértes; Ildikó Zsófia Juhász; Tin Dat Nguyen; Dániel Sándor Veres; Artúr Hüttl; Balázs Nemes; Kálmán Hüttl; Edit Dósa
Journal:  J Endovasc Ther       Date:  2018-08-20       Impact factor: 3.487

4.  Mortality and complications after aortic bifurcated bypass procedures for chronic aortoiliac occlusive disease.

Authors:  Kim Bredahl; Leif Panduro Jensen; Torben V Schroeder; Henrik Sillesen; Henrik Nielsen; Jonas P Eiberg
Journal:  J Vasc Surg       Date:  2015-07       Impact factor: 4.268

5.  Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis.

Authors:  S O de Vries; M G Hunink
Journal:  J Vasc Surg       Date:  1997-10       Impact factor: 4.268

Review 6.  Kissing stent reconstruction of the aortoiliac bifurcation.

Authors:  Melhem J Sharafuddin; Jamal J Hoballah; Timothy F Kresowik; William J Sharp
Journal:  Perspect Vasc Surg Endovasc Ther       Date:  2008-04-02

7.  The influence of gender on patency rates after iliac artery stenting.

Authors:  Beate Bechter-Hugl; Jürgen Falkensammer; Olaf Gorny; Andreas Greiner; Andreas Chemelli; Gustav Fraedrich
Journal:  J Vasc Surg       Date:  2014-02-16       Impact factor: 4.268

8.  Percutaneous transluminal angioplasty in the region of the aortic bifurcation. The two-balloon technique with results and long-term follow-up study.

Authors:  C J Tegtmeyer; C D Kellum; I L Kron; R M Mentzer
Journal:  Radiology       Date:  1985-12       Impact factor: 11.105

9.  Aortofemoral dacron reconstruction for aorto-iliac occlusive disease: a 25-year survey.

Authors:  A Nevelsteen; L Wouters; R Suy
Journal:  Eur J Vasc Surg       Date:  1991-04

10.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.